Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluating the Utility of RELiZORB™ for Treating Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
Sponsor: Inova Health Care Services
Summary
The purpose of this research is to determine if the use of RELiZORB™ improves nutrition tolerance and helps critically ill patients meet their nutrition goals. RELiZORB™ is a digestive enzyme cartridge that contains lipase and works as a pancreatic enzyme replacement. It promotes breaking down fat and helps the body absorb it. The device connects with tube feedings to help the body with digestion. RELiZORB™ is approved by the U.S. Food and Drug Administration (FDA) for use with tube feedings in patients 5 years of age or older. While the use of RELiZORB™ in this study is consistent with the FDA approval, the use of RELiZORB™ in patients with multi organ failure is not in the current standard of care practice at Inova Health Care facilities.
Official title: Single-center, Proof of Concept, Prospective Study Evaluating the Utility of RELiZORB™ for the Treatment of Feeding Intolerance in Critically Ill Adults With Multi-Organ Failure
Key Details
Gender
All
Age Range
18 Years - 89 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-05-07
Completion Date
2026-05-31
Last Updated
2026-02-04
Healthy Volunteers
No
Interventions
RELiZORB™
RELiZORB cartridges will be used with routine enteral feedings for 5 days for randomized participants
Placebo
Placebo cartridges will be used with routine enteral feedings for 5 days for randomized participants
Locations (1)
Inova Fairfax Medical Campus
Falls Church, Virginia, United States